• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Activities of Omadacycline against Rapidly Growing Mycobacteria.奥马环素对快速生长分枝杆菌的活性。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02522-18. Print 2019 May.
2
Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria.替加环素、依拉环素、奥马环素和沙雷环素对快速生长分枝杆菌的抗菌活性。
Microbiol Spectr. 2023 Feb 14;11(1):e0323822. doi: 10.1128/spectrum.03238-22. Epub 2022 Dec 8.
3
Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria.奥马环素对非结核分枝杆菌的药敏试验。
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01947-20.
4
Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of .新型四环素类似物奥马环素和依拉环素对.耐药临床分离株的活性
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00470-19. Print 2019 Jun.
5
Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.甘氨酰环素替加环素(原GAR-936)与四环素、米诺环素和多西环素对非结核分枝杆菌分离株的体外活性比较。
Antimicrob Agents Chemother. 2002 Oct;46(10):3164-7. doi: 10.1128/AAC.46.10.3164-3167.2002.
6
In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria.新型恶唑烷酮类药物DA - 7867和DA - 7157对快速生长和缓慢生长分枝杆菌的体外活性
Antimicrob Agents Chemother. 2006 Dec;50(12):4027-9. doi: 10.1128/AAC.00763-06. Epub 2006 Oct 2.
7
Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.脓肿分枝杆菌、龟分枝杆菌和偶发分枝杆菌肉汤微量稀释法药敏试验结果的多中心可重复性。
J Clin Microbiol. 1999 Jun;37(6):1676-82. doi: 10.1128/JCM.37.6.1676-1682.1999.
8
In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan.异帕米星、其他氨基糖苷类药物及卷曲霉素对台湾快速生长分枝杆菌临床分离株的体外活性
Antimicrob Agents Chemother. 2007 May;51(5):1849-51. doi: 10.1128/AAC.01551-06. Epub 2007 Mar 12.
9
Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.用于脓肿分枝杆菌、龟分枝杆菌和偶发分枝杆菌药敏试验的Etest的多中心再现性。
J Clin Microbiol. 2000 Feb;38(2):656-61. doi: 10.1128/JCM.38.2.656-661.2000.
10
In vitro activity of TP-271 against Mycobacterium abscessus, Mycobacterium fortuitum, and Nocardia species.TP-271 对脓肿分枝杆菌、偶然分枝杆菌和诺卡氏菌属的体外活性。
Antimicrob Agents Chemother. 2012 Jul;56(7):3986-8. doi: 10.1128/AAC.00743-12. Epub 2012 May 14.

引用本文的文献

1
In Vitro Susceptibility to Imipenem/Relebactam and Comparators in a Multicentre Collection of Complex Isolates.多中心复杂分离株集合中对亚胺培南/瑞来巴坦及对照药物的体外敏感性
Antibiotics (Basel). 2025 Jul 5;14(7):682. doi: 10.3390/antibiotics14070682.
2
Targeting Autophagy as a Strategy for Developing New Host-Directed Therapeutics Against Nontuberculous Mycobacteria.以自噬为靶点开发抗非结核分枝杆菌新型宿主导向疗法的策略
Pathogens. 2025 May 13;14(5):472. doi: 10.3390/pathogens14050472.
3
Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis.奥马环素在成年囊性纤维化患者中的药代动力学
Clin Pharmacokinet. 2024 Dec;63(12):1701-1709. doi: 10.1007/s40262-024-01440-w. Epub 2024 Nov 24.
4
Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of lung disease.在肺部疾病的小鼠模型中,比较了 omadacycline+阿米卡星+亚胺培南和全口服 omadacycline+氯法齐明+利奈唑胺两种方案的疗效。
mSphere. 2024 Jul 30;9(7):e0038124. doi: 10.1128/msphere.00381-24. Epub 2024 Jul 9.
5
Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation.利用氧乐酶克服药物降解挑战对非结核分枝杆菌进行奥马环素药物敏感性测试。
Tuberculosis (Edinb). 2024 Jul;147:102519. doi: 10.1016/j.tube.2024.102519. Epub 2024 May 13.
6
Exploring antibiotic resistance mechanisms in for enhanced therapeutic approaches.探索[具体对象]中的抗生素耐药机制以改进治疗方法。 (你提供的原文“Exploring antibiotic resistance mechanisms in for enhanced therapeutic approaches.”中“in for”之间缺少具体内容,我根据语境补充了“[具体对象]”,你可根据实际情况调整)
Front Microbiol. 2024 Feb 6;15:1331508. doi: 10.3389/fmicb.2024.1331508. eCollection 2024.
7
Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine.治疗非结核分枝杆菌感染的药物:来自意大利传染病和热带医学学会分枝杆菌研究组的叙述性综述。
Infection. 2024 Jun;52(3):737-765. doi: 10.1007/s15010-024-02183-3. Epub 2024 Feb 8.
8
Non-tuberculous mycobacterial disease: progress and advances in the development of novel candidate and repurposed drugs.非结核分枝杆菌病:新型候选药物和再利用药物研发的进展与突破。
Front Cell Infect Microbiol. 2023 Oct 2;13:1243457. doi: 10.3389/fcimb.2023.1243457. eCollection 2023.
9
Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes.奥马环素治疗非结核分枝杆菌感染的临床疗效和安全性的长期评估:一项回顾性、多中心真实世界健康结局的队列研究。
Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0082423. doi: 10.1128/aac.00824-23. Epub 2023 Sep 28.
10
Long-term Safety and Tolerability of Omadacycline for the Treatment of Infections.奥马环素治疗感染的长期安全性和耐受性
Open Forum Infect Dis. 2023 Jul 3;10(7):ofad335. doi: 10.1093/ofid/ofad335. eCollection 2023 Jul.

本文引用的文献

1
Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.新型氨基甲基环素类抗生素奥马环素的发现、药理学及临床概况
Bioorg Med Chem. 2016 Dec 15;24(24):6409-6419. doi: 10.1016/j.bmc.2016.07.029. Epub 2016 Jul 18.
2
In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline.奥马环素的体外和体内抗菌活性,一种新型的氨甲基环素。
Antimicrob Agents Chemother. 2014;58(2):1127-35. doi: 10.1128/AAC.01242-13. Epub 2013 Dec 2.
3
Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease.非结核分枝杆菌来自非结核分枝杆菌病患者的家庭管道。
Emerg Infect Dis. 2011 Mar;17(3):419-24. doi: 10.3201/eid1703.101510.
4
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.美国胸科学会/美国感染病学会官方声明:非结核分枝杆菌病的诊断、治疗与预防
Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416. doi: 10.1164/rccm.200604-571ST.

奥马环素对快速生长分枝杆菌的活性。

Activities of Omadacycline against Rapidly Growing Mycobacteria.

机构信息

Central New York Research Corporation, Syracuse, New York, USA

Central New York Research Corporation, Syracuse, New York, USA.

出版信息

Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02522-18. Print 2019 May.

DOI:10.1128/AAC.02522-18
PMID:30858221
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6496053/
Abstract

The activity of omadacycline, a new tetracycline derivative, was evaluated against isolates of , , and using a broth microtiter dilution assay. Omadacycline had MIC values of 2 μg/ml, 0.25 μg/ml, and 0.5 μg/ml, respectively. The activity of omadacycline against rapidly growing mycobacteria indicates that it may have the potential to improve therapy for infections caused by these organisms.

摘要

新型四环素衍生物奥马环素的活性采用肉汤微量稀释法对 、 、 分离株进行了评估。奥马环素的 MIC 值分别为 2μg/ml、0.25μg/ml 和 0.5μg/ml。奥马环素对快速生长分枝杆菌的活性表明,它可能具有改善这些生物体引起的感染治疗的潜力。